Literature DB >> 24861358

Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE.

J Zweegers1, J M P A van den Reek, P C M van de Kerkhof, M E Otero, P M Ossenkoppele, M D Njoo, J M Mommers, M I A Koetsier, W P Arnold, B A M Sybrandy-Fleuren, A L A Kuijpers, M P M Andriessen, W Kievit, E M G J de Jong.   

Abstract

BACKGROUND: Treatment goals have been developed to optimize daily clinical practice psoriasis care, but have not yet been studied in real life.
OBJECTIVES: To investigate to what extent treatment decisions made by dermatologists in daily clinical practice for patients with psoriasis on biologics are already in accordance with treatment goals without the active application of the treatment goals algorithm.
METHODS: Data were extracted from a prospective daily practice cohort of patients with psoriasis on biologics. Analysis was done on effectiveness (Psoriasis Area and Severity Index score) and quality of life (Dermatology Life Quality Index questionnaire). Treatment decisions such as dosage adjustments, combination treatments, or switching therapy were compared with the treatment goals algorithm.
RESULTS: In 64% (253 of 395) of visits, physicians followed the treatment goals algorithm. There were 162 (41%) visits in which there should have been a treatment modification according to treatment goals (group Modify) and a modification was indeed made in 59 of these 162 visits (36%). In 233 (59%) visits no treatment modification was necessary (group Continue) and therapy was indeed not modified in 194 of 233 visits (83%).
CONCLUSIONS: Physicians acted in accordance with treatment goals in the majority of patient visits. In the patient group not achieving these goals, physicians should have modified therapy according to treatment goals but continued the same therapeutic regimen in the majority of visits. Optimizing therapy and defining barriers in the latter group might increase treatment results in daily practice psoriasis care.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861358     DOI: 10.1111/bjd.13137

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.

Authors:  N H Shear; M Hartmann; M E Toledo-Bahena; M Gilbert; A Katsambas; R Yao; Z Popmihajlov
Journal:  Qual Life Res       Date:  2016-02-11       Impact factor: 4.147

2.  The Skin May Clear But the Arthritis Won't Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy.

Authors:  Marloes E van Muijen; Tamara W van Hal; Hans M M Groenewoud; Juul M P A van den Reek; Elke M G J de Jong
Journal:  Psoriasis (Auckl)       Date:  2020-10-05

3.  Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab.

Authors:  Marloes E van Muijen; S Atalay; L J van Vugt; L M D Vandermaesen; J M P A van den Reek; E M G J de Jong
Journal:  Drugs Real World Outcomes       Date:  2021-03-28

4.  Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report.

Authors:  Sang Woong Youn; Bo Ri Kim; Joo Heung Lee; Hae Jun Song; Yong Beom Choe; Ji Ho Choi; Nack In Kim; Kwang Joong Kim; Jai Il Youn
Journal:  Ann Dermatol       Date:  2015-03-24       Impact factor: 1.444

5.  Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians.

Authors:  Y Okubo; D Tsuruta; A C Tang; S Inoue; H Torisu-Itakura; T Hanada; M Ohtsuki
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-06       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.